Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine vs SSRIs in Elderly Depression
NCT03779789Phase 4Completed
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Feb 2019
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vortioxetine in major depressive disorder (MDD) (2 arms), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: Number of participants withdrawing from treatment due to adverse events (tolerability) at 6 months. Started Feb 2019; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03779789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03779789.